Sarepta Therapeutics (NASDAQ:SRPT) Given “Outperform” Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $37.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on SRPT. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, March 2nd. Citigroup upped their target price on Sarepta Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, March 10th. Mizuho increased their target price on Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Finally, Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Nine analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $32.15.

Sarepta Therapeutics Stock Down 3.0%

SRPT stock opened at $16.65 on Thursday. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $80.26. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The firm’s fifty day moving average is $18.97 and its 200 day moving average is $19.94. The firm has a market cap of $1.75 billion, a PE ratio of -1.97, a P/E/G ratio of 0.27 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The firm had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. During the same quarter last year, the company posted $1.90 EPS. The company’s revenue was down 32.7% on a year-over-year basis. On average, research analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares in the company, valued at $30,040.30. The trade was a 80.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. AQR Capital Management LLC boosted its holdings in Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after purchasing an additional 6,390,860 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 18.1% during the 3rd quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after buying an additional 1,657,267 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after buying an additional 1,312,220 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Sarepta Therapeutics by 183.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after buying an additional 1,129,610 shares during the period. Finally, Erste Asset Management GmbH raised its position in shares of Sarepta Therapeutics by 65.7% during the 3rd quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after buying an additional 1,064,530 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.